Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Dynamics analysis of an amended HBV infection model with a simulation for anti-HBV infection therapy

Xiao ChenSchool of Informatics, Linyi University, Linyi, Shandong, CNKaiyun SunSchool of Mathematical Sciences, Shandong Normal University, Jinan, Shandong, CNJianlong QiuSchool of Sciences, Linyi University, Linyi, Shandong, CNXiangyong ChenSchool of Informatics, Linyi University, Linyi, Shandong, CNChengdong YangSchool of Sciences, Linyi University, Linyi, Shandong, CNAncai ZhangSchool of Sciences, Linyi University, Linyi, Shandong, CN
2014en
ABI

Аннотация

This paper introduces an amended hepatitis B virus (HBV) infection model with an immune response term and an alanine aminotransferase (ALT) term. It has been proved that if a basic virus reproductive number R <inf xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</inf> < 1, then the virus free equilibrium point of the model is globally asymptotically stable; if R <inf xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</inf> > 1, then the immune depletion equilibrium point of the model is globally asymptotically stable. This result implies that if an HBV infected patient has R <inf xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">0</inf> < 1, then the patient will eventually recover even if infected with a large amount of virus. Simulating the dynamics of evolutions of serum HBV DNA levels and ALT levels for 115 Asians and 113 non-Asians HBeAg positive chronic hepatitis B (CHB) patients' Tenofovir Disoproxil Fumarate (TDF) 48 weeks therapy reported by C. Pan et al., the results show that TDF anti-HBV infection therapy may not only suppress the HBV DNA levels via destructing patients' infected hepatocytes but also activate patients' ability of cytokine-midiated non-cytolytic HBV clearance, which clears HBV directly without damaging patients' hepatocytes.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0